218 related articles for article (PubMed ID: 15634232)
1. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
3. Low grade diffuse gliomas: shared cellular composition and morphometric differences.
Kinjo S; Hirato J; Nakazato Y
Neuropathology; 2008 Oct; 28(5):455-65. PubMed ID: 18282166
[TBL] [Abstract][Full Text] [Related]
4. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
Hirose T; Ishizawa K; Shimada S
Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
[TBL] [Abstract][Full Text] [Related]
5. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
6. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
7. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype?
Tanaka Y; Yokoo H; Komori T; Makita Y; Ishizawa T; Hirose T; Ebato M; Shibahara J; Tsukayama C; Shibuya M; Nakazato Y
Acta Neuropathol; 2005 Jul; 110(1):39-47. PubMed ID: 15906048
[TBL] [Abstract][Full Text] [Related]
8. Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status.
Durand K; Guillaudeau A; Pommepuy I; Mesturoux L; Chaunavel A; Gadeaud E; Porcheron M; Moreau JJ; Labrousse F
J Clin Pathol; 2011 Sep; 64(9):793-801. PubMed ID: 21653654
[TBL] [Abstract][Full Text] [Related]
9. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II.
Stockhammer F; von Deimling A; van Landeghem FK
Histopathology; 2009 Jan; 54(2):241-7. PubMed ID: 19207949
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
Barresi V; Buttarelli FR; Vitarelli EE; Arcella A; Antonelli M; Giangaspero F
Hum Pathol; 2009 Dec; 40(12):1738-46. PubMed ID: 19716156
[TBL] [Abstract][Full Text] [Related]
12. Diversity of glial cell components in pilocytic astrocytoma.
Tanaka Y; Sasaki A; Ishiuchi S; Nakazato Y
Neuropathology; 2008 Aug; 28(4):399-407. PubMed ID: 18312545
[TBL] [Abstract][Full Text] [Related]
13. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
14. OLIG2 as a specific marker of oligodendroglial tumour cells.
Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
[TBL] [Abstract][Full Text] [Related]
15. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Marko NF; Prayson RA; Barnett GH; Weil RJ
Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
[TBL] [Abstract][Full Text] [Related]
16. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
17. Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours.
Reyaz N; Tayyab M; Khan SA; Siddique T
J Coll Physicians Surg Pak; 2005 Aug; 15(8):472-5. PubMed ID: 16202357
[TBL] [Abstract][Full Text] [Related]
18. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors.
Aguirre-Cruz L; Mokhtari K; Hoang-Xuan K; Marie Y; Criniere E; Taillibert S; Lopes M; Delattre JY; Sanson M
J Neurooncol; 2004 May; 67(3):265-71. PubMed ID: 15164981
[TBL] [Abstract][Full Text] [Related]
20. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
